title: Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate.
abstract: Recent experimental and clinical pharmacological studies on colloidal bismuth subcitrate (CBS) are reviewed. CBS combines with mucus to produce a marked retardation of the movement of hydrogen ions. CBS has potent anti-ulcer and anti-erosive action in various experimental models in animals, and is able to stimulate the generation of gastric mucosal prostaglandins. CBS is thought to be a cytoprotective agent. The type of mucosal cell repair in the vicinity of the ulcer is favourably affected in man. CBS also exhibits anti-pepsin and bile acid-binding properties. Pyloric campylobacter are inhibited in vitro and in vivo. The recent pharmacological findings are discussed in the light of the clinical efficacy of CBS and new indications.
mesh_terms: D000818:Animals; D001729:Bismuth / Q000494:pharmacology*; D002167:Campylobacter / Q000472:pathogenicity; D015232:Dinoprostone; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000209:etiology; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology; D005756:Gastritis / Q000209:etiology; D006801:Humans; D009942:Organometallic Compounds; D011458:Prostaglandins E / Q000096:biosynthesis
chemical_list: D009942:Organometallic Compounds; D011458:Prostaglandins E; C002791:bismuth tripotassium dicitrate; D015232:Dinoprostone; D001729:Bismuth